Table 2.
The relationship between PSADT with adverse pathology and biochemical progression.
| PSADT ≤ 18 mos |
PSADT > 18 mos |
p-value | PSADT ≤36 mos |
PSADT >36 mos |
p-value | |
|---|---|---|---|---|---|---|
| Organ- confined |
254 (75%) | 651 (76%) | 0.71 | 446 (73%) | 459 (79%) | 0.018 |
| Extracapsular extension |
38 (11%) | 91 (11%) | 0.76 | 72 (12%) | 57 (10%) | 0.26 |
| Positive margins |
70 (21%) | 169 (20%) | 0.81 | 135 (22%) | 104 (18%) | 0.083 |
| Seminal vesicle invasion |
12 (4%) | 19 (2%) | 0.23 | 21 (3%) | 10 (2%) | 0.07 |
| Lymph node metastases |
2 (0.6%) | 3 (0.4%) | 0.63 | 3 (0.5%) | 2 (0.4%) | 0.99 |
| Prostatectomy Gleason ≥7 |
85 (26%) | 197 (24%) | 0.49 | 153 (26%) | 129 (23%) | 0.22 |
| Biochemical progression |
58 (17%) | 133 (15%) | 0.54 | 96 (16%) | 95 (16%) | 0.75 |
| 10-Year Progression- free survival |
80% | 82% | 0.54 | 82% | 80% | 0.66 |
*
Comparisons of pathologic features made using the chi-square tests. 10-year progression-free survival was calculated using the Kaplan-Meier method and compared by the log-rank test.